From our beginnings in 1991 as a systems company built on medical statistics, the EPS Group has responded to customer needs amid structural changes in the market and increasingly rigorous and complex drug development. EPS has evolved as a CRO (Contract Research Organization) and expanded our offerings to include SMO (Site Management Organization) and CSO (Contract Sales Organization) services, thereby becoming a comprehensive provider of various support services for the healthcare industry. CRO： In response to requests from pharmaceutical, medical device and regenerative medicine companies, medical institutions, governmental agencies, and others, the EPS CRO Group provides One-Stop Solutions to support the development of pharmaceuticals, medical devices, foods, and cosmetics. SMO： The EPS SMO Group enhances clinical trials by collaboration with medical institutions across Japan, leveraging digital technology to improve efficiency, including the promotion of Decentralized Clinical Trials (DCTs) and the development of remote systems for clinical trial document management. CSO： The EPS CSO provides targeted support to pharmaceutical and medical device manufacturers after product approval. We provide contact center operations, and a range of services from pre-approval to post-marketing stages, employing a skilled workforce to effectively fulfill customer needs. | EPS Holdings, Inc., a Japanese headquartered company, is a comprehensive provider of clinical trial and research outsourced services. EPS Group, with over 7,800 staff, provides quality support to pharmaceutical, biotech, regenerative medicine, and medical device companies. Core businesses are CRO, SMO, Contract Sales Support, and China product development and distribution. EPS operates in Japan, China, South Korea, and Taiwan and, through a partner, supports studies in other Asia-Pacific countries. Looking towards the future, we will strengthen our forward-looking spirit expressed as an “Ever Progressing System.” | The EPS Group was founded in 1991 as a pioneer in the domestic Contract Research Organization (CRO) industry. Since then, we have expanded our diverse services, including Site Management Organization (SMO) and Contract Sales Organization (CSO), with a primary focus on CRO. We provide end-to-end support solutions from the development of pharmaceuticals, medical devices, and regenerative medicine products to post-marketing surveillance. Building on the foundation of our clinical trial and post-marketing businesses, which boast a top-tier scale and proven track record in Japan, we are actively engaging in data business and new ventures, constantly striving for evolution.
EFOR Group
Founded in 2013, Efor Group is a leading international player in quality and compliance for the Life Sciences industry. With over 3,000 employees across 18 countries, Efor supports leading pharmaceutical, biotech, and medtech companies in securing their manufacturing operations through its expertise in CQV, quality management, and regulatory compliance, while accelerating the delivery of innovative therapies to market. Our mission: to remove technical and regulatory barriers, enabling faster access to innovation while ensuring the highest standards of safety and reliability. Committed to its founding values, Efor fully integrates social and environmental responsibility into its business model and drives sustainable growth built on excellence, commitment, and teamwork. Through its international expansion, the Group aims to establish itself as a global reference in Life Sciences consulting, placing people, health, and safety at the heart of everything it does.
DXY Insight Database
DXY Insight Database is a leading global drug competitive intelligence platform with deep China insights, delivering multi-dimensional intelligence across the entire drug lifecycle — from preclinical research through post-market approval — and empowering enterprises to make more precise decisions and work more efficiently. Key highlights include: · 80,000+ drug pipelines (22,000+ originated by Chinese companies) · 25,000+ pharmaceutical companies (11,000+ based in China) · Tracking of 9,000+ targets and 14,000+ BD transactions
Divamics Inc
Divamics Inc. is a cross-disciplinary company with the core technology of AI and physics force field, helping collaborators to hunt new hits and PCCs in a more efficient and accurate way, especially for undrugable targets. Also, we offer clinical insights, such as resistance analyses and expansion of drug indications. Our signature capacities include drug design for GPCR, allosteric sites, and PPI, transcription factors. Our targeting modalities cover small molecules, peptides, PROTAC, XDC, synthetic biology, and more. We have already collaborated with 25+ MNCs/bioteches to advance over 35 new drug development pipelines and achieved multiple breakthrough results. Our records include: *FIC Project: Pioneering Drug Development* 1. Proposed binding site hypotheses, enabling the creation of drugs from scratch 2. Identified hits within 30 syntheses in a FIC pipeline with no pre-existing clinical drugs *BIC Project: Revolutionizing Structural Optimization* 1. Combined SAR computational analysis with expert medicinal chemistry insights to innovate structural optimization 2. Achieved patent breakthrough and better potency within just 6 syntheses of peptides, currently in Phase II clinical trials; Phase II clinical trial data to be presented at the ADA Conference, June 2024 We want to find collaborators such as the early discovery departments of MNCs, biopharmaceuticals and biotechs, with flexible cooperation modes including strategic joint research and others. | Divamics Inc. is a cross-disciplinary company with the core technology of AI and physics force field, helping collaborators to HUNT NEW LEADs and PCCs in a more efficient and accurate way, especially for UNDRUGGABLE targets. Also, we offer clinical insights, such as resistance analyses and expansion of drug indications. Currently, we have 40+ partners (10 listed companies/MNCs, 2 USA biotechs) for 60 pipeline projects, while 2 of them have reached end of Phase Ⅲ. We work on strategic collaboration mode, or offer AI+DBDD services, based on our partners’ needs. | Divamics: Redefining the Speed of Precision Medicine Divamics is an AI-driven biotech leader accelerating the journey from hit identification to preclinical candidate (Hits-to-PCC). By integrating advanced AI with molecular dynamics, we provide biopharma partners with the clarity and confidence to make critical discovery decisions faster. With a proven track record of supporting 80+ pipelines for over 50 global partners, we have successfully reduced PCC discovery timelines to just 0.5 – 1.5 years. Our platform delivers unmatched precision across four key modalities: small molecules, peptides, antibodies, and nucleic acids.
Daxiang Biotech
Daxiang Biotech is a leading innovator in organoid-on-a-chip technologies in China and a global provider of integrated microphysiological systems (MPS) solutions for drug discovery, translational research, and precision medicine. Founded in 2018, the company has established a fully integrated, end-to-end platform spanning design, modeling, R&D, manufacturing, and application of human-relevant in vitro systems. Powered by its core technology framework—Organoid-on-a-Chip + AI + Automation—Daxiang develops proprietary instruments, chips, reagents, and advanced human-relevant models to help global life sciences partners improve preclinical decision-making and accelerate development timelines. At the core of its technology is the IBAC® (Integrated Biomimetic Array Chip) platform, which integrates stem cell biology, organoid science, and microfluidics to recreate physiologically relevant human tissue environments in vitro. Based on this platform, Daxiang has developed 50+ organoid culture kits and 100+ humanized physiological and disease models across oncology, liver, gastrointestinal, kidney, brain, and cardiovascular applications. Daxiang’s technologies have been validated by third-party institutions and adopted by leading pharmaceutical companies, biotechnology companies, hospitals, and research institutes. The company has supported multiple IND-enabling programs, helping partners improve translational predictability and reduce reliance on animal models in selected applications. Daxiang Biotech is actively seeking global partnerships with pharmaceutical and biotech companies, CRO/CDMO organizations, research institutions, distributors, and strategic investors. Key collaboration interests include drug discovery services, translational model co-development, precision medicine applications, regional commercialization, and AI-enabled next-generation preclinical platforms.
Dasher Neuroscience Inc.
Dasher Neuroscience is dedicated to pioneering research in central nervous system (CNS) diseases. By integrating artificial intelligence (AI) technology, Dasher Neuroscience aims to drive groundbreaking advances, offering innovative treatment options for patients worldwide.
Cytiva
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery. We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more. | Diagnostic assays like the ones you’re developing are in demand. Set yourself up for success by choosing a supplier that delivers quality products for your entire workflow and offers specialized services and capabilities needed to commercialize your assays. Using a single supplier for multiple components, from membranes to magnetic beads, can streamline your development process and ultimately accelerate the commercialization of diagnostic assays and kits. Cytiva can help you speed up and scale up without staffing up! With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical knowledge and talent, a broad and deep portfolio, and exceptional service to support biotechs at every stage from discovery to delivery. Visit cytiva.com/diagnostics to learn more. | Cytiva and Pall Life Sciences have come together to deliver the breadth, depth, and scale researchers and biopharma need to advance future therapeutics – from discovery to delivery. Together, as Cytiva, we supply the tools and support our customers need to work better, faster and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. | Cytiva is a global life sciences leader that works with academic and translational researchers, developers and manufacturers of biotherapeutics, cell and gene therapies, and new technologies such as mRNA, to enable the delivery of transformative medicines. Cytiva is a trusted expert with nearly 10 000 associates in 43 countries dedicated to customers’ speed, flexibility, capacity and efficiency in drug discovery, research, and manufacturing.
CRQA
CRQA: Your Trusted GxP Compliance and Regulatory Consulting Partner Company: CRQA (Compliance, Regulatory & Quality Assurance) Headquarters: Noida, Uttar Pradesh, India (Office No. 602, 6th Floor, Tower B, B8 Noida One, Sector 62) Website: www.crqa.in Contact: bd@crqa.in | +91 98100 68241 Tagline: GxP Compliance: We have got you covered Who We Are CRQA is an independent, specialized auditing and regulatory consulting organization headquartered in New Delhi/Noida, India. Unlike large contract research organizations (CROs) that offer quality assurance as an add-on, CRQA was built exclusively around GxP compliance — making regulatory excellence our sole focus, not a side offering. Registered with Dun & Bradstreet, ISO 13485 & ISO 9011:2015 certified, and recognized as an MSME, CRQA has positioned itself as a credible and conflict-free compliance partner for pharmaceutical companies, biotechnology firms, clinical research organizations, medical device manufacturers, and healthcare institutions worldwide. Global Reach CRQA operates across more than 60 countries and delivers its services in 30 languages, making it one of the most geographically diverse independent GxP auditing firms in the world. Our network of Auditors spans: • Asia: India, Japan, China, Southeast Asia, including major Indian cities — New Delhi NCR, Noida, Gurgaon, Mumbai, Pune, Bangalore, Chennai, Hyderabad, Kolkata, Ahmedabad, Vadodara • Americas: United States, Latin America • Europe: EU countries, UK • Middle East & Africa • Australia & Oceania This wide geographical presence enables us to deploy region-based auditors who understand local regulatory environments — reducing travel costs and turnaround time for our clients. Why CRQA? — The Value Proposition CRQA was founded to address a critical gap in the pharmaceutical services industry: the absence of a dedicated, independent auditing agency free from conflicts of interest. Key advantages of working with CRQA: ✔ No conflict of interest — CRQA is purely an auditing and consulting firm; we do not run clinical trials or offer CRO services, ensuring full objectivity in every audit. ✔ Specialized expertise — Our auditors are seasoned professionals with deep GxP knowledge, offering a level of focus that generalist CROs cannot match. ✔ Cost efficiency — With locally based auditors across 60+ countries, clients benefit from significant cost savings on travel and logistics. ✔ Better sponsor–CRO relationships — By outsourcing audits to CRQA rather than using competitor CROs, sponsors can maintain neutral, healthy vendor relationships. ✔ Holistic compliance perspective — Our external auditors provide an unbiased, big-picture view of a client’s systems, identifying gaps and improvement opportunities that internal teams may overlook. Services Portfolio CRQA provides a comprehensive suite of GxP auditing and regulatory consulting services: Clinical & Research Compliance • GCP (Good Clinical Practice) Audits and Services • GCP Consultancy • Mock Inspections • BA/BE (Bioavailability/Bioequivalence) CRO Audits • Remote GCP and Pharmacovigilance Audits • Vendor Audits • Study Audits Manufacturing & Distribution Quality • GMP (Good Manufacturing Practice) Audits and Services • GDP (Good Distribution Practice) Compliance • GLP/GCLP (Good Laboratory/Clinical Laboratory Practice) Audits • Pharmaceutical Quality Management Services Pharmacovigilance & Drug Safety • Pharmacovigilance Audits • QPPV (Qualified Person for Pharmacovigilance) Services • Global Pharmacovigilance Outsourcing Services Medical Devices • Medical Device Regulatory Audits and Consulting • ISO 13485 Quality Management System Support Regulatory Affairs & Strategy • Regulatory Pathway Consulting Services • Global Pharmaceutical Outsourcing Services • Dossier Submission Support (Feasibility to Filing) • Qualified Person (QP) Services in Europe Technology & Systems Compliance • Computer System Validation (CSV) • Compliance Training on 21 CFR Part 11 Quality Systems & SOPs • Quality Management and Compliance Systems • SOPs Development and Review Training & Education • Online Training and Workshops • Ethics Committee / IRB Training • Compliance Training Programs Key Clients CRQA has earned the trust of a diverse global clientele, including recognized names across pharma, biotech, medical devices, and healthcare and have worked with wide range of pharma, biopharma and medical device clients from USA, Europe, India. Certifications & Recognition • D-U-N-S Registered (Dun & Bradstreet Verified) • ISO 13485 Certified (Medical Devices Quality Management Systems) • ISO 9001 : 2015 • MSME Recognized (Government of India) Our Differentiator at BIO USA At a conference where partnerships are forged and life sciences innovation meets business strategy, CRQA stands out as the go-to independent partner for: • Pharma and biotech companies entering new markets who need local regulatory audit support • CROs and sponsors seeking objective, third-party GxP compliance evaluations • Medical device companies needing ISO 13485 audits and regulatory consulting • Global life sciences firms looking for cost-effective, scalable compliance solutions across multiple geographies Whether you are preparing for an FDA, EMA, or CDSCO inspection, building your quality management infrastructure, or seeking ongoing pharmacovigilance oversight — CRQA delivers expert, independent, and conflict-free compliance support. Connect With Us at BIO USA kshahani@crqa.in +91 98100 68241 www.crqa.in LinkedIn: CRQA India CRQA — GxP Compliance: We Have Got You Covered.
COD Research USA Inc
COD Research is a leading CRO based in the US and India, specializing in global clinical trials and pharmacovigilance services. With a strong focus on biosimilar trials worldwide, we offer tailored solutions, ensuring quality, compliance, and client satisfaction. Our commitment is to contribute to the advancement of healthcare by delivering reliable and efficient services on an international scale. | We are a technical full-service Contract Research Organization (CRO) that offers end-to-end Clinical Trial Services, complemented by an industry-leading suite of specialized Pharmacovigilance Solutions. Our flexible working models are designed to seamlessly integrate with your teams, whether you require functional services for global studies or tailored on-site and off-site support. | We are a technical Full Service CRO that offers end-to-end Clinical Trial Services, complemented by an industry-leading suite of specialized Pharmacovigilance Solutions. Our flexible working models are designed to seamlessly adapt to client requirements, whether you require functional solutions or global studies or tailored on-site and off-site support.
CheckImmune GmbH
CheckImmune is an innovative immune biomarker CRO for preclinical and clinical programs. As a spin-off company of Charité Universitätsmedizin Berlin we have strong links to academic state-of-the art research. CheckImmune is providing biomarker studies with focus on novel immunotherapeutics (small molecules, biologics, Advanced Therapy Medicinal Products – ATMPs) and immunological challenges in other medical areas. CheckImmune is specialized in the development and validation of immunological biomarkers for global clinical trials and accredited according to ISO 17025 and 15189 with fulfilling the requirements of GCLP (Good Clinical Laboratory Practice). Our core expertise includes assay development and validation for Receptor Occupancy, Flow Cytometry, Multiplex Cytokine Analyses, Functional Tests, Single Cell Multiomics, and Tissue Biopsies. We are a certified service provider for 10x Genomics, Olink, and ProteinSimple Ella. We are a team of well recognized experts for immune biomarker analyses and data interpretation. Our Services are Selection/validation of drug lead candidates, Phase 0 studies with access to fresh patient material, Therapy monitoring (safety, efficacy/stratification) and Data analysis and scientific & medical interpretation. At CheckImmune, we develop highly specialized immunological biomarker assays and provide end-to-end lab services for clinical and preclinical trials. From assay design to regulatory-grade data analysis – we help biopharma companies understand immune responses with precision. We are a certified service provider for 10x Genomics, OLINK and bio-techne. With a track record of more than 90 industry-sponsored trials and 120,000 samples we have earned an excellent international reputation. Selection/validation of drug lead candidates Application of a broad panel of customized and off-the-shelf biomarker tests using cutting-edge technologies for lead candidate selection. Phase 0 studies with access to fresh patient material Proof-of-concept studies on biosamples from target patient populations (phase 0) to develop and confirm selected biomarker test portfolios for following therapy monitoring. Therapy monitoring Therapy monitoring in clinical trials to check safety, PD/PK, patient stratification with a wide range of validated assays as well as newly developed customized methods. Data analysis and scientific & medical interpretation CheckImmune is backed by a world-renowned team of experts with years of academic and commercial experience in the field of immune biomarkers. Technology used Our Technology platforms are – Complex Flow & Spectral Cytometry – Molecular & Multi-Omics Analysis: Bulk RNAseq, TCR /BCR repertoire, Single cell Multiomics (RNAseq, TCRseq, CITEseq) Spatial multi-omics, qRT- PCR (e.g. IFN signature) and digitalPCR – Multiplex Ligand Assays (MSD, Ella, OLINK) – Functional Assays – Anti-Drug Response (ADA/ADT)